首页 Esperion Therapeutics(usESPR)-基本信息

Esperion Therapeutics(usESPR)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:28.02

最高价:28.11

成交量:356439.0

昨收价:28.22

最低价:26.83

最新价:26.95

行情图标
概要信息

英文名称:Esperion Therapeutics


简介:Esperion Therapeutics, Inc.于2008年1月在特拉华州注册成立


电话:1-734-8873903


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Esperion Therapeutics, Inc.是一家专注于研究、开发与商业化口服及低密度脂蛋白胆固醇降低疗法,用于治疗高胆固醇血症及其他心血管代谢基本的生物制药公司,Esperion Therapeutics公司产品包括: ETC-1002,一种口服分子药物,用于治疗患者高胆固醇血症、降低低密度胆固醇水平,以及避免各种与降低低密度胆固醇疗法相关联的副作用,目前处于IIb临床试验阶段; 4WF,一个综合的脂蛋白AI(apoA-I)疗法,用于治疗急性冠心症,目前已完成IIa阶段临床试验; ESP41091,用于脂质代谢及降低身体重量(减肥),目前处于临床前阶段。Esperion Therapeutics(ESPR)历史沿革: 1998年5月,Esperion Therapeutics成立; 2000年,Esperion Therapeutics登陆纳斯达克,股票代码:ESPR; 2003年12月,辉瑞公司(Pfizer)为了防止Esperion正在研究的ETC-216落入竞争对手手中,以13亿美金防御性收购了Esperion; 2007年,Pfizer决定终止ETC-216的研究; 2008年5月,Pfizer将Esperion出售给了Roger Newton,从此,又再成为一家独立公司; 2013年6月,Esperion IPO,第二次登陆纳斯达克,股票代码保持不变:ESPR。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-22 Biotech Target N V Beneficial Owner of More than 10% Class Buy 50000 42.65
2019-06-27 Mayleben (Timothy M) Chief Executive Officer Buy 5000 46.00
2019-05-28 Janney (Daniel Spencer) Director Buy 4967 --
2019-05-28 Gotto (Antonio M Jr) Director Buy 4967 --
2019-05-28 Braunstein (Scott N. M.D.) Director Buy 4967 --
2019-05-28 McGovern (Mark E) Director Buy 4967 --
2019-05-28 Shepard Jay P Director Buy 4967 --
2019-05-28 Berkowitz Jeffrey Director Buy 4967 --
2019-05-28 Vitullo (Nicole) Director Buy 4967 --
2019-05-28 Woody (Tracy M) Director Buy 9934 --
2019-04-02 Bartram (Richard B) Chief Financial Officer Sell 1500 43.62
2019-04-02 Bartram (Richard B) Chief Financial Officer Sell 6500 42.71
2019-03-28 Mayleben (Timothy M) Chief Executive Officer Buy 5000 40.00
2019-03-20 Vitullo (Nicole) Director Sell 17790 --
2019-03-20 Vitullo (Nicole) Director Buy 1356 --
2019-03-19 Mayleben (Timothy M) Chief Executive Officer Buy 5000 43.48
2019-03-18 Vitullo (Nicole) Director Sell 13629 44.66
2019-03-18 Vitullo (Nicole) Director Buy 17790 --
2019-03-18 Vitullo (Nicole) Director Sell 1700 45.25
2019-03-18 Vitullo (Nicole) Director Sell 1101080 --
2019-03-13 Mayleben (Timothy M) Chief Executive Officer Buy 5000 48.73
2019-03-13 Biotech Target N V Beneficial Owner of More than 10% Class Buy 50000 49.89
2019-03-11 Newton (Roger S) Director Sell 25000 50.06
2019-01-03 Biotech Target N V Beneficial Owner of More than 10% Class Buy 80000 41.29
2018-12-23 Biotech Target N V Beneficial Owner of More than 10% Class Buy 50000 39.91

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Bellevue Group AG 495547 1.84% 43575 9.64% 2019-03-31
Partner Fund Management LP 1627079 6.04% -251924 -13.41% 2019-03-31
Vanguard Group Inc 1757423 6.53% 59353 3.50% 2019-03-31
BlackRock Inc 1857673 6.90% -21226 -1.13% 2019-03-31
Pentwater Capital Management LP 2476500 9.20% -10800 -0.43% 2019-03-31
Meditor Group Ltd 2679835 9.96% -- -- 2019-03-31
Meditor Capital Management Limited 2679835 9.96% -- -- 2019-03-31
BB Biotech AG 3522964 13.09% 130000 3.83% 2019-03-31
Bellevue Asset Management AG 3962936 14.72% 3000 0.08% 2019-07-31
State Street Corporation 1388090 5.16% -119159 -7.91% 2019-03-31
Credit Suisse First Boston (CSFB) 1149415 4.27% 177780 18.30% 2019-03-31
BlackRock Fund Advisors 1123919 4.18% 12435 1.12% 2019-07-31
HBM Partners Cayman Ltd 535278 1.99% -35979 -6.30% 2019-07-31
Nomura Holdings Inc 550000 2.04% 85300 18.36% 2019-03-31
Fidelity Management and Research Company 561432 2.09% -156157 -21.76% 2019-03-31
FMR Inc 579236 2.15% -160053 -21.65% 2019-03-31
Wasatch Advisors Inc. 637789 2.37% 75165 13.36% 2019-03-31
Vanguard Investments Australia Ltd 722391 2.68% -14 -- 2019-07-31
Boxer Capital LLC 975000 3.62% -225000 -18.75% 2019-03-31
SSGA Funds Management Inc 1084873 4.03% 20900 1.96% 2019-07-31
BlackRock Asset Management Canada Ltd 537816 2.00% -84 -0.02% 2019-05-31
Geode Capital Management, LLC 550820 2.05% 295813 116.00% 2018-12-31
Fidelity Management & Research Company 571187 2.12% -375776 -39.68% 2019-04-30
Bank of Nova Scotia 515010 1.92% 175010 51.47% 2018-09-30
DOMAIN PARTERS VII LP 1887852 7.04% 1887852 -- 2017-12-06
Aviva Holdings Ltd 1200100 4.47% -- -- 2018-09-30
Northern Trust Investments N A 626639 2.34% 36535 6.19% 2018-09-30
Northern Trust Corp 626639 2.34% 36535 6.19% 2018-09-30
BlackRock Institutional Trust Company NA 620573 2.31% 104177 20.17% 2018-06-30
Fidelity SelectCo, LLC 616197 2.30% -115975 -15.84% 2018-11-30
Rhenman Partners Asset Management AB 406361 -- 161821 66.17% 2018-06-30
Wells Fargo Bank NA 449628 -- 240070 114.56% 2018-06-30
Alta Partners Management VIII, LLC 627219 -- -732748 -53.88% 2017-12-20
Braslyn Ltd. 1200000 -- 860000 252.94% 2018-05-02
State Street Corp 2173737 -- 859024 65.34% 2018-06-30
Pinnacle Associates Inc 632131 -- -27672 -4.19% 2018-03-31
Pioneer Investment Mgmt Inc 294730 -- 56346 23.64% 2018-03-31
T. Rowe Price Associates, Inc. 294844 -- 104757 55.11% 2018-03-31
Citadel Advisors Llc 458027 -- 284335 163.70% 2018-03-31
Discovery Capital Management LLC 475175 -- -307884 -39.32% 2017-12-31
Balyasny Asset Management LLC 403164 1.53% 10014 2.55% 2017-12-31
Millennium Management LLC 387947 1.47% 354580 1062.67% 2017-12-31
Aisling Capital LLC 837125 3.20% -- -- 2017-09-30
RA Capital Management, LLC 731531 3.24% 26830 3.81% 2017-06-30
ING Investment Management LLC 689910 3.06% -241450 -25.92% 2016-09-30
Bvf Inc 493872 2.19% -5270 -1.06% 2016-09-30
Renaissance Technologies Corp 318800 1.41% 318800 -- 2016-09-30
Granahan Investment Management Inc.. 248030 1.10% -- -- 2016-09-30
Deutsche Bank AG 247313 1.10% 232334 1551.06% 2016-09-30
Invesco Advisers, Inc 175970 0.78% -- -- 2016-09-30
J.P. Morgan Investment Management Inc 148600 0.66% 42600 40.19% 2016-09-30
Entities affiliated with FMRLLC 1401274 3.00% 87509561 0.10% 1999-11-30
Patrick G. Enright 1434396 3.00% 89578030 0.10% 1999-11-30
Pentwater Capital ManagementLP 1470000 3.00% 91801500 0.10% 1999-11-30
Daniel Janney 1709967 3.00% 106787439 0.10% 1999-11-30
Dov A. Goldstein, M.D. 2054594 3.00% 128309395 0.10% 1999-11-30
Nicole Vitullo 2602188 3.00% 162506641 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 120726 0.45% -- -- 2019-06-30
SPDR 1065201 3.96% 20900 2.00% 2019-07-31
Vanguard Total Stock Market Index Fund 716551 2.66% 20 -- 2019-06-30
iShares Russell 2000 ETF 554686 2.06% 11725 2.16% 2019-07-30
HBM Healthcare Investments AG 535278 1.99% -35979 -6.30% 2019-06-30
Rhenman Healthcare Eq L/S 434814 1.62% -44953 -9.37% 2019-04-30
BB Healthcare 434572 1.61% 15000 3.58% 2018-12-31
Vanguard Extended Market Index Fund 343322 1.28% 76 0.02% 2019-06-30
Vanguard Small Cap Index 324114 1.20% 6912 2.18% 2019-06-30
iShares Nasdaq Biotechnology ETF 265720 0.99% 3796 1.45% 2019-07-30
Pioneer Select Mid Cap Growth Fund 254561 0.95% -- -- 2019-05-31
Invesco Dynamic Biotech & Genome ETF 132566 0.49% 5762 4.54% 2019-07-31
Pinnacle Small Mid Cap Equity-UBS 158996 0.59% 158996 -- 2019-06-30
Wasatch Ultra Growth Fund 171002 0.64% 18896 12.42% 2019-06-30
Vanguard Small Cap Growth Index Fund 187349 0.70% 8358 4.67% 2019-06-30
Baron Discovery Fund 188500 0.70% 5000 2.72% 2019-06-30
Wasatch Small Cap Growth Fund 212807 0.79% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 228904 0.85% 2895 1.28% 2019-07-30
Pictet-Biotech 206255 0.77% -852 -0.41% 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 470096 1.75% -792 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 313747 1.17% 858 0.27% 2019-04-30
State Street Russell Small/Mid Cap 100284 0.37% 5300 5.58% 2019-03-31
Wasatch Micro Cap Fund 98439 0.37% 4892 5.23% 2018-12-31
GAM Multistock Health Innovation Equity 91193 0.34% -7500 -7.60% 2018-11-30
Tekla Healthcare Investors 104858 0.39% -- -- 2018-09-30
Arctic Aurora LifeScience 102922 0.38% 24000 30.41% 2018-11-30
Northern Small Cap Value Fund 150198 0.56% -11389 -7.05% 2018-09-30
Fidelity Advisor 196220 0.73% -7375 -3.62% 2018-07-31
Variopartner Sectoral Biotech Opps Fd 114368 0.43% -- -- 2018-06-30
Wells Fargo Small Company Growth Fund 126701 0.47% 4256 3.48% 2018-08-31
iShares Nasdaq Biotechnology 303297 1.07% -576 -0.19% 2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 55980 0.21% -172 -0.31% 2018-07-31
Fidelity Spartan 36331 0.14% 2639 7.83% 2018-04-30
Schwab US Small-Cap ETF 57171 0.21% -- -- 2018-09-13
Wasatch Micro Cap 75988 0.28% 29409 63.14% 2018-06-30
Voya SmallCap Opportunities A 98590 0.37% 22000 28.72% 2018-06-30
Vanguard Total Stock Mkt Idx 599518 2.24% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 271306 1.01% 1700 0.63% 2018-07-31
iShares Russell 2000 Growth 220572 0.78% -213 -0.10% 2018-09-12
Pioneer Select Mid Cap Growth A 236577 0.88% -- -- 2018-06-30
Wasatch Small Cap Growth Investor 230904 0.86% -56469 -19.65% 2018-06-30
Vanguard Small Cap Growth Index Inv 173248 0.65% 3031 1.78% 2018-07-31
Northern Small Cap Value 161587 0.60% -- -- 2018-06-30
Wells Fargo Small Company Growth Admin 122444 0.46% 51 0.04% 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 52084 0.23% 1392 2.75% 2017-06-30
Optimum Small-Mid Cap Growth A 51759 0.19% 31048 149.91% 2018-03-31
Voya Small Cap Growth Trust 34495 0.13% 34495 -- 2018-03-31
PowerShares DWA Healthcare Momentum ETF 70741 0.26% -- -- 2018-06-28
Vanguard Health Care ETF 45890 0.17% -873 -1.87% 2018-04-30
TIAA-CREF Small-Cap Equity Instl 84200 0.32% -- -- 2018-02-28
Lord Abbett Micro Cap Growth I 40960 0.16% -13269 -24.47% 2018-01-31
iShares Micro-Cap 38569 0.14% -- -- 2018-03-21
iShares Russell 2000 Value 133501 0.98% -528 -0.39% 2017-02-07
Vanguard Explorer Inv 174800 0.78% -- -- 2016-09-30
Pru Ret Small Cap Value/Kennedy SP 83710 0.37% 60120 254.85% 2016-12-31
AST Small Cap Value 50800 0.23% -- -- 2016-12-31
Wasatch Ultra Growth 42773 0.19% 13021 43.77% 2016-12-31
Vanguard VIF Small Co Gr 37950 0.17% -- -- 2016-09-30
BioShares 21674 0.16% -- -- 2017-02-08
Schwab Instl Small Cap Tr Fd-Instl 30401 0.13% -18683 -38.06% 2016-09-30
SPDR® S&P Biotech ETF 503345 2.50% 3280 0.70% 2015-11-19
Biotech Growth Trust Plc 424000 1.90% 424000 -- 2015-07-31
Fidelity Advisor® Biotechnology Fund 402493 1.80% -- -- 2015-09-30
Polar Capital Healthcare Opps 277224 1.20% -7118 -2.50% 2015-09-30
DWS Vermögensbildungsfonds 230000 0.80% -- -- 2015-09-30
iShares Russell 2000 (AU) 207697 1.00% -264 -0.10% 2015-11-19
Vanguard Explorer Fund 173000 0.80% 13000 8.10% 2015-09-30
DWS Biotech 150000 0.50% -- -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 1922778 8.50% -- -- 2015-09-30

Dov A. Goldstein Dr. Dov A. Goldstein is Operating Partner at Aisling Capital LLC. He is on the Board of Directors at Esperion Therapeutics, Inc., Cempra Pharmaceuticals, Inc., Cempra, Inc., ADMA Biologics, Inc. and ADMA Plasma Biologics, Inc. Dr. Goldstein was previously employed as Chief Financial Officer by Loxo Oncology, Inc., Chief Financial Officer by Vicuron Pharmaceuticals, Inc., and Director-Venture Analysis by HealthCare Ventures LLC. He also served on the board at Durata Therapeutics, Inc., Scerene Healthcare, Inc. and Topaz Pharmaceuticals, Inc. He received his undergraduate degree from Stanford University, an MBA from Columbia Business School and a doctorate degree from Yale School of Medicine.
Dan S. Janney Presently, Dan S. Janney occupies the position of Chairman of Allakos, Inc., Managing Director & Director at Alta Bioequities Management LLC and Managing Director at Alta Partners Management Corp. Mr. Janney is also on the board of 9 other companies. In his past career Mr. Janney held the position of Director at Sutro Biopharma, Inc., Chairman of Viveve Medical, Inc., Vice President of Montgomery Securities, Inc., Associate at Bankers Trust Co. (Des Moines, Iowa) and Member-President's Council at The J. David Gladstone Institutes. He received an undergraduate degree from Georgetown University and an MBA from UCLA Anderson School of Management.
Gil S. Omenn Dr. Gil S. Omenn is an Independent Director at Galectin Therapeutics, Inc., an Independent Director at Esperion Therapeutics, Inc., an Executive VP-Medical Affairs & Professor at University of Michigan, an Affiliate Faculty at Institute for Systems Biology, a Member at American Academy of Arts & Sciences, a Member at Association of American Physicians, a Member at Institute of Medicine, a Member-Community Preventive Services Task Force of Centers for Disease Control & Prevention, a Member-Scientific Management Review of National Institutes of Health and a Vice President at Human Proteome Organization. He is on the Board of Directors at Galectin Therapeutics, Inc., Esperion Therapeutics, Inc., Armune BioScience, Inc., Life Sciences Society, Oncofusion Therapeutics, Inc., Population Services International, Salzburg Global Seminar, Inc., The Center for Public Integrity, The Hastings Center, US Civilian Research & Development Foundation and The CNA Corp. Dr. Omenn was previously employed as a Chief Executive Officer by University of Michigan Health System, an Independent Director by Amgen, Inc., a Professor by University of Washington, an Associate Director by Office of Science & Technology Policy, a Member by American College of Physicians, Inc. /Old/, an Advisor by Arboretum Ventures, Inc., and a Chairman by tranSMART Foundation. He also served on the board at Etubics Corp., OccuLogix, Inc., Rohm & Haas Co., American Association for the Advancement of Science, Fred Hutchinson Cancer Research Center and United Way Foundation. He received his undergraduate degree from Princeton University, a doctorate degree from Harvard Medical School and a doctorate degree from the University of Washington.
Antonio M. Gotto Dr. Antonio M. Gotto is a Scientific Advisor at Frantz Medical Ventures, In addition to his current role with Vatera Healthcare Partners, Dr. Gotto has been Dean of the Weill Medical College of Cornell University and Provost for Medical Affairs for Cornell University since January 1997. He is also a Avdisor at Yellowstone Capital. He was a Director for Medtronic. from 1992 to August 24, 2006. He was Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital from 1977 to 1996. He was J.S. Abercrombie Chairman for Atherosclerosis and Lipoprotein Research from 1976 to 1996. He was President for International Atherosclerosis Society and American Heart Association. He is a Member of the Institute of Medicine of the National Academy of Sciences. He is a Fellow of the American Academy of Arts and Sciences. Dr. Gotto was awarded a Doctor of Philosophy from Oxford University in England in 1961, where he was a Rhodes Scholar. He received his Doctor of Medicine from Vanderbilt University School of Medicine in 1965, and completed his residency training at Massachusetts General Hospital in Boston.
Nicole Vitullo Ms. Nicole Vitullo is a Director at Rosetta Capital Ltd., Partner at Domain Associates LLC, Managing Member at One Palmer Square Associates VIII LLC and a Principal at Bioscience Managers Pty Ltd. She is on the Board of Directors at Achillion Pharmaceuticals, Inc., Esperion Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Celtaxsys, Inc., Cotera, Inc. and VentiRx Pharmaceuticals, Inc. Ms. Vitullo was previously employed as an Independent Director by Durata Therapeutics, Inc., an Independent Director by Celator Pharmaceuticals, Inc., Senior Vice President by Rothschild Asset Management, Inc., Director-Corporate & Investor Communications by Cephalon, Inc., and a Principal by Eastman Kodak Co. She also served on the board at Onyx Pharmaceuticals, Inc., Calixa Therapeutics, Inc., Cerexa, Inc., Eunoe, Inc. and Psyadon Pharmaceuticals, Inc. Ms. Vitullo received her undergraduate degree from the University of Rochester and an MBA from the University of Rochester.
Jay P. Shepard Jay P. Shepard is a businessperson who founded Relypsa, Inc. and who has been the head of 5 different companies. Currently, he is Chief Executive Officer & Director at Aravive, Inc. He is also on the board of 9 other companies. In his past career Mr. Shepard held the position of Principal at Syntex Laboratories, Inc., Venture Partner at Sofinnova Ventures, Inc., President, Chief Executive Officer & Director at NextWave Pharmaceuticals, Inc., President, CEO, CFO & Director at Versartis, Inc., President, Chief Executive Officer & Director at Ilypsa, Inc., Principal at Ortho Pharmaceutical Corp., Vice President-Commercial Operations at Telik, Inc., Vice President for ALZA Corp. and Vice President-Oncology Business Unit at ALZA Pharmaceuticals. He received an undergraduate degree from the University of Arizona.
Roger S. Newton Dr. Roger S. Newton is a Co-Founder & Managing Director at Esperance BioVentures LLC. He is on the board of various private and public companies. Dr. Newton co-founded Esperance BioVentures in July 1998. Before that, he was a Research Fellow in Vascular and Cardiac Diseases at Parke-Davis where he was a co-developer of Lipitor. Dr. Newton has a PhD in Nutrition from The University of California-Davis, an MS degree in Nutritional Biochemistry from The University of Connecticut and a BS in Biology from Lafayette College.
Tim M. Mayleben Mr. Tim M. Mayleben is Co-Founder & Managing Director at Esperance BioVentures LLC. He is on the board of various private and public companies. Prior to co-founding Esperance BioVentures in July 1998, Mr. Mayleben was the Chief Operating Officer of Esperion Therapeutics, now a division of Pfizer Global Research & Development. He also worked for Transom Technologies, Inc., a simulation software company. He has held various financial and operating management positions with Applied Intelligent Systems, Inc. He started his professional career with an international public accounting firm in 1984. Mr. Mayleben has a BBA from The University of Michigan Business School and an MBA with distinction from Northwestern University-Kellogg Graduate School of Management.
Mark E. McGovern Mark E. McGovern is on the board of Esperion Therapeutics, Inc. In his past career he occupied the position of Executive Director-Heart Failure at Bristol-Myers Squibb Co. and Chief Medical Officer & Executive Vice President at KOS Pharmaceuticals, Inc. He received an undergraduate degree from Princeton University and a doctorate from the University of Vermont.
Scott N. Braunstein Dr. Scott N. Braunstein, MD, is an Independent Director at Constellation Pharmaceuticals, Inc., an Independent Director at Trevena, Inc., an Executive Chairman at ArTara Therapeutics, Inc., an Independent Director at Esperion Therapeutics, Inc. and a Chief Operating Officer & Director at Stat Medical Services, Inc. He is on the Board of Directors at Constellation Pharmaceuticals, Inc., Trevena, Inc., ZIOPHARM Oncology, Inc., SiteOne Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Esperion Therapeutics, Inc., Stat Medical Services, Inc. and Cornell University College of Agriculture & Life Sciences. Dr. Braunstein was previously employed as a Chief Operating Officer by Pacira Pharmaceuticals, Inc., a Portfolio Manager by EverPoint Asset Management LLC, a Principal by Deutsche Bank AG, a Vice President-Operations by Defined Health, Inc., an Assistant Clinical Professor by Albert Einstein College of Medicine, Inc., an Assistant Clinical Professor by Columbia University Medical Center, a Managing Director by JPMorgan Investment Management, Inc., and a Physician by Summit Medical Group LLC. He received his undergraduate degree from Cornell University and a doctorate degree from Albert Einstein College of Medicine, Inc..
Tracy M. Woody Tracy M. Woody is on the board of Esperion Therapeutics, Inc. In her past career she was Managing Director at Tmw Consulting, Inc., Chief Executive Officer at Retroject, Inc., Chief Commercial Officer of KemPharm, Inc., Senior Manager-Marketing at Pfizer Inc., Vice President-Business Development of Greer Laboratories, Inc., Chief Commercial Officer at Versartis, Inc. and Vice President-Sales & Marketing at NextWave Pharmaceuticals, Inc. She received an undergraduate degree from East Carolina University.
William J. Sasiela Currently, William J. Sasiela occupies the position of Senior Vice President-Clinical Development at Esperion Therapeutics, Inc. He previously occupied the position of Clinical Director at Lipitor, Vice President-Program Direction at Regeneron Pharmaceuticals, Inc. and Chief Medical Officer & Executive VP-Clinical at Aegerion Pharmaceuticals, Inc. He received an undergraduate degree from Virginia Polytechnic Institute & State University and a doctorate from the University of South Carolina School of Medicine.
Jeffrey Berkowitz Presently, Jeffrey Berkowitz occupies the position of Chief Executive Officer & Director at Real Endpoints LLC. Mr. Berkowitz is also on the board of 6 other companies. Mr. Berkowitz previously occupied the position of Executive Vice President at UnitedHealth Group, Inc. and Executive Vice President for Optum, Inc. (a subsidiary of UnitedHealth Group, Inc.), Attorney at Proskauer Rose LLP, Executive Vice President at Walgreens Boots Alliance, Inc. Co-President at Walgreens Boots Alliance Development GmbH and SVP-Pharmaceutical Development & Market Access at Walgreen Co. (both are subsidiaries of Walgreens Boots Alliance, Inc.) and Senior Vice President-Global Market Access at Merck & Co., Inc. and Vice President-Global Market Access at Schering-Plough Corp. (a subsidiary of Merck & Co., Inc.). Mr. Berkowitz received an undergraduate degree from Union College (New York) and a graduate degree from Brooklyn Law School.
Narendra D. Lalwani Currently, Narendra D. Lalwani holds the position of Executive Vice President-Research & Development at Esperion Therapeutics, Inc. In the past he was Chief Scientific Officer at Cerenis Therapeutics Holding SA and Chief Scientific Officer at Cerenis Therapeutics, Inc. (a subsidiary of Cerenis Therapeutics Holding SA) and Principal at Pfizer Inc. and Principal at Parke, Davis & Co. LLC (a subsidiary of Pfizer Inc.). Narendra D. Lalwani received a doctorate from the University of Mumbai, an undergraduate degree from Gujarat University and an MBA from Stephen M. Ross School of Business.
Scott N. Braunstein Dr. Scott N. Braunstein, MD, is an Independent Director at Constellation Pharmaceuticals, Inc., an Independent Director at Trevena, Inc., an Executive Chairman at ArTara Therapeutics, Inc., an Independent Director at Esperion Therapeutics, Inc. and a Chief Operating Officer & Director at Stat Medical Services, Inc. He is on the Board of Directors at Constellation Pharmaceuticals, Inc., Trevena, Inc., ZIOPHARM Oncology, Inc., SiteOne Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Esperion Therapeutics, Inc., Stat Medical Services, Inc. and Cornell University College of Agriculture & Life Sciences. Dr. Braunstein was previously employed as a Chief Operating Officer by Pacira Pharmaceuticals, Inc., a Portfolio Manager by EverPoint Asset Management LLC, a Principal by Deutsche Bank AG, a Vice President-Operations by Defined Health, Inc., an Assistant Clinical Professor by Albert Einstein College of Medicine, Inc., an Assistant Clinical Professor by Columbia University Medical Center, a Managing Director by JPMorgan Investment Management, Inc., and a Physician by Summit Medical Group LLC. He received his undergraduate degree from Cornell University and a doctorate degree from Albert Einstein College of Medicine, Inc..
Jeffrey Berkowitz Presently, Jeffrey Berkowitz occupies the position of Chief Executive Officer & Director at Real Endpoints LLC. Mr. Berkowitz is also on the board of 6 other companies. Mr. Berkowitz previously occupied the position of Executive Vice President at UnitedHealth Group, Inc. and Executive Vice President for Optum, Inc. (a subsidiary of UnitedHealth Group, Inc.), Attorney at Proskauer Rose LLP, Executive Vice President at Walgreens Boots Alliance, Inc. Co-President at Walgreens Boots Alliance Development GmbH and SVP-Pharmaceutical Development & Market Access at Walgreen Co. (both are subsidiaries of Walgreens Boots Alliance, Inc.) and Senior Vice President-Global Market Access at Merck & Co., Inc. and Vice President-Global Market Access at Schering-Plough Corp. (a subsidiary of Merck & Co., Inc.). Mr. Berkowitz received an undergraduate degree from Union College (New York) and a graduate degree from Brooklyn Law School.
Marianne Andreach Presently, Marianne Andreach is Senior Vice President-Product Planning at Esperion Therapeutics, Inc. In her past career she occupied the position of Senior Director-Business Development at The Medicines Co. Ms. Andreach received an undergraduate degree from College of the Holy Cross (Massachusetts).
Marianne Andreach Presently, Marianne Andreach is Senior Vice President-Product Planning at Esperion Therapeutics, Inc. In her past career she occupied the position of Senior Director-Business Development at The Medicines Co. Ms. Andreach received an undergraduate degree from College of the Holy Cross (Massachusetts).
Richard B. Bartram Richard B. Bartram occupies the position of Chief Financial Officer & Secretary of Esperion Therapeutics, Inc. In his past career Mr. Bartram was Assurance Manager at PricewaterhouseCoopers LLP. Mr. Bartram received a graduate degree and an undergraduate degree from Michigan State University.
Alexander Duke Schwartz Presently, Alexander Duke Schwartz holds the position of Senior Director-Investor Relations at Esperion Therapeutics, Inc. He previously held the position of Principal at Schonfeld Securities LLC and Senior Associate at Stifel, Nicolaus & Co., Inc. Mr. Schwartz received an undergraduate degree from Kelley School of Business and an MBA from Wallace E Carroll School of Management.
Ashley Hall Currently, Ashley Hall holds the position of Senior VP-Global Regulatory Affairs & Policy at Esperion Therapeutics, Inc. Ms. Hall previously held the position of Vice President-Regulatory & Clinical Affairs at Revogenex Ltd., Director-World Wide Regulatory Affairs at Medimmune, Inc., Vice President-Regulatory Affairs for Amgen Rockville, Inc. and Vice President-Regulatory Affairs of CancerVax Corp. Ashley Hall received a graduate degree from the University of San Diego School of Law and an undergraduate degree from the University of California San Diego.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐